IMAZODAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H12N4O
Molecular Weight	240.2606
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1CCC(=NN1)C2=CC=C(C=C2)N3C=CN=C3

InChI

InChIKey=VXMYWVMXSWJFCV-UHFFFAOYSA-N

InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1715125 | https://adisinsight.springer.com/drugs/800000379

Imazodan, a phosphodiesterase III inhibitor was developed by Parke-Davis to treat heart failure and ischemic heart disorders. However, the study of this drug was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 60 Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2559580 \| https://medkoo.com/products/10206	Inhibitor 8297

PubMed

Title	Date	PubMed
Mechanisms of leptin secretion from white adipocytes.	2002 Jul	12055093

Sample Use Guides

In Vivo Use Guide

Patients were randomized to placebo or 2, 5 or 10 mg of imazodan administered twice daily.

Route of Administration: Oral

Name

Type

Language

IMAZODAN

Official Name

English

imazodan [INN]

Common Name

English

IMAZODAN [MART.]

Common Name

English

4,5-DIHYDRO-6-(P-IMIDAZOL-1-YLPHENYL)-3(2H)-PYRIDAZINONE

Common Name

English

3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(4-(1H-IMIDAZOL-1-YL)PHENYL)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744